Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients

NCT00158730 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT00158730
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00158730 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Safety and Efficacy of AmBisome Loading Dose Regimen Vs. a Standard AmBisome Regimen for Initial Treatment of Invasive Aspergillosis and Other Filamentous Fungal Infections in Immunocompromised Patients
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2003
Completion date
January 31, 2005
Enrollment
800
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

invasive aspergillosis, other fungal infections